Laboratory of Lymphocyte Signaling and Oncoproteome

TCL1 expression in plasmacytoid dendritic cells (DC2) and the related CD4+CD56+ blastic tumors of skin

Herling, M Teitell, MA Shen, RR Medeiros, LJ Jones, D
Blood 101, 12June, 2003Pages: 5007-9doi: 10.1182/blood-2002-10-3297

Initially considered to be of natural killer (NK)–cell origin, CD4+ CD56+ blastic tumors (BTs) of skin have recently been proposed to be of dendritic cell lineage. We have previously described BTs with transformation to myelomonocytic leukemia. Here we report expression of the lymphoid proto-oncogene TCL1 in 10 (83%) of 12 BTs and in lymph node plasmacytoid dendritic cells (DC2s). TCL1 was also expressed in myelomonocytic blasts of 3 transformed BT cases but not in true NK-cell tumors (n = 18), de novo acute myelomonocytic leukemias (1 of 14, 7%), or mature T-cell malignancies (1 of 112, < 1%), with the exception of T-prolymphocytic leukemia (T-PLL). All BT cases were also positive for the DC2-associated marker CD123. These results further support derivation of BTs from DC2s, and demonstrate that TCL1 expression in this tumor is common to the immature blastoid, lymphoid-appearing, and subsequent myelomonocytic phases of this disease.

Full text


Alkylating deacetylase inhibitor tinostamustine in T-PLL

March 11, 2020

New letter evaluating the effects of EDO-S101/tinostamustine published in Leukemia.

Advances and Perspectives in the Treatment of T-PLL

Advances and Perspectives in the Treatment of T-PLL

February 25, 2020

New review on current and future strategies in treating T-PLL published in Current Hematologic Malignancy Reports

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL

November 21, 2019

New meta-analysis on JAK/STAT genomic alterations in T-PLL published in Cancers.

We congratulate Dr. Sebastian Oberbeck on his PhD defence!

We congratulate Dr. Sebastian Oberbeck on his PhD defence!

October 30, 2019

On October 30th, Sebastian Oberbeck successfully defended his PhD. Congratulations!